购物车
- 全部删除
- 您的购物车当前为空
BJE6-106 (B106) is a potent, selective PKCδ inhibitor (IC50: 0.05 μM) and targets selectivity over classical PKCα (IC50: 50 μM). BJE6-106 induces caspase-dependent apoptosis with tumor-specific effect.
为众多的药物研发团队赋能,
让新药发现更简单!
BJE6-106 (B106) is a potent, selective PKCδ inhibitor (IC50: 0.05 μM) and targets selectivity over classical PKCα (IC50: 50 μM). BJE6-106 induces caspase-dependent apoptosis with tumor-specific effect.
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
2 mg | ¥ 2,520 | 5日内发货 | |
5 mg | ¥ 2,890 | 5日内发货 | |
25 mg | ¥ 10,600 | 6-8周 | |
50 mg | ¥ 13,800 | 6-8周 | |
100 mg | ¥ 17,500 | 6-8周 | |
1 mL x 10 mM (in DMSO) | ¥ 3,180 | 5日内发货 |
产品描述 | BJE6-106 (B106) is a potent, selective PKCδ inhibitor (IC50: 0.05 μM) and targets selectivity over classical PKCα (IC50: 50 μM). BJE6-106 induces caspase-dependent apoptosis with tumor-specific effect. |
靶点活性 | PKCδ:0.05 μM, PKCα:50 μM |
体外活性 | BJE6-106 (0.2 μM, 0.5 μM; 6-24 hours) triggers caspase-dependent apoptosis, increases the activity of caspase 3/7, the effect of B106 is greater than rottlerin (10-fold) in SBcl2 cells. BJE6-106 (0.2 μM, 0.5 μM; 24-72 hours) suppresses cell survival in melanoma cell lines with NRAS mutations. BJE6-106 (0.5 μM; 2-10 hours) activates the MKK4-JNK-H2AX Pathway by inducing JNK, MKK4, and H2AX activation at different times in SBcl2 cells. |
别名 | B106 |
分子量 | 381.47 |
分子式 | C26H23NO2 |
CAS No. | 1564249-38-2 |
密度 | 1.16 g/cm3 (Predicted) |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容